GENTEX CORP
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Shareholders' Investment
For the Three Months Ended June 30, 2026 and 2025
| Common StockShares | Common StockAmount | Additional Paid-InCapital | Retained Earnings | Accumulated OtherComprehensiveIncome (Loss) | Total | Equity Attributable to Noncontrolling Interests | Total Shareholders’Investment | |
|---|---|---|---|---|---|---|---|---|
| BALANCE AS OF APRIL 1, 2026 | 212,979,921 | $12,778,795 | $1,007,716,711 | $1,480,867,060 | $1,222,600 | $2,502,585,166 | $— | $2,502,585,166 |
| Issuance of common stock from stock plan transactions | 424,869 | 25,492 | 1,883,539 | — | — | 1,909,031 | — | 1,909,031 |
| Repurchases of common stock | (2,696,740) | (161,804) | (11,272,373) | (54,586,203) | — | (66,020,380) | — | (66,020,380) |
| Stock-based compensation expense related to stock options, employee stock purchases and restricted stock | — | — | 9,733,390 | — | — | 9,733,390 | — | 9,733,390 |
| Dividends declared ($0.12 per share) | — | — | — | (25,283,964) | — | (25,283,964) | — | (25,283,964) |
| Net income (1) | — | — | — | 114,689,417 | — | 114,689,417 | — | 114,689,417 |
| Other comprehensive income | — | — | — | — | 488,098 | 488,098 | — | 488,098 |
| BALANCE AS OF JUNE 30, 2026 | 210,708,050 | $12,642,483 | $1,008,061,267 | $1,515,686,310 | $1,710,698 | $2,538,100,758 | $— | $2,538,100,758 |
| BALANCE AS OF APRIL 1, 2025 | 224,817,117 | $13,489,027 | $1,011,756,899 | $1,454,610,199 | $(5,030,122) | $2,474,826,003 | $4,591,500 | $2,479,417,503 |
| Issuance of common stock from stock plan transactions | 405,697 | 24,342 | 1,392,640 | — | — | 1,416,982 | — | 1,416,982 |
| Repurchases of common stock | (5,702,064) | (342,124) | (22,865,277) | (102,955,530) | — | (126,162,931) | — | (126,162,931) |
| Stock-based compensation expense related to stock options, employee stock purchases and restricted stock | — | — | 7,488,526 | — | — | 7,488,526 | — | 7,488,526 |
| Dividends declared ($0.12 per share) | — | — | — | (26,342,490) | — | (26,342,490) | — | (26,342,490) |
| Fair value of non-controlling interest in EyeLock LLC | — | — | — | — | — | — | 656,000 | 656,000 |
| Purchase of additional interest in BioCenturion LLC | — | — | 1,139,021 | — | — | 1,139,021 | (4,591,549) | (3,452,528) |
| Net income (loss) (1) | — | — | — | 96,039,584 | — | 96,039,584 | (56,395) | 95,983,189 |
| Other comprehensive income | — | — | — | — | 1,633,473 | 1,633,473 | — | 1,633,473 |
| BALANCE AS OF JUNE 30, 2025 | 219,520,750 | $13,171,245 | $998,911,809 | $1,421,351,763 | $(3,396,649) | $2,430,038,168 | $599,556.00 | $2,430,637,724 |
(1)Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $505,646 and $332,739 for the three months ended June 30, 2026 and 2025, respectively (see Note 16).
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' INVESTMENT
For the Six Months Ended June 30, 2026 and 2025
| Common StockShares | Common StockAmount | Additional Paid-InCapital | Retained Earnings | Accumulated OtherComprehensiveIncome (Loss) | Total | Equity Attributable to Noncontrolling Interests | Total Shareholders’Investment | |
|---|---|---|---|---|---|---|---|---|
| BALANCE AS OF JANUARY 1, 2026 | 215,445,024 | 12,926,701 | 1,008,589,267 | 1,466,046,002 | 267,754 | 2,487,829,724 | $— | $2,487,829,724 |
| Issuance of common stock from stock plan transactions | 1,212,462 | 72,748 | 3,940,070 | — | — | 4,012,818 | — | 4,012,818 |
| Repurchases of common stock | (5,949,436) | (356,966) | (24,608,425) | (112,662,914) | — | (137,628,305) | — | (137,628,305) |
| Stock-based compensation expense related to stock options, employee stock purchases and restricted stock | — | — | 20,140,355 | — | — | 20,140,355 | — | 20,140,355 |
| Dividends declared ($0.24 per share) | — | — | — | (50,841,338) | — | (50,841,338) | — | (50,841,338) |
| Net income (1) | — | — | — | 213,144,560 | — | 213,144,560 | — | 213,144,560 |
| Other comprehensive income | — | — | — | — | 1,442,944 | 1,442,944 | — | 1,442,944 |
| BALANCE AS OF JUNE 30, 2026 | 210,708,050 | $12,642,483 | $1,008,061,267 | $1,515,686,310 | $1,710,698 | $2,538,100,758 | $— | $2,538,100,758 |
| BALANCE AS OF JANUARY 1, 2025 | 227,207,472 | $13,632,448 | $1,010,440,420 | $1,450,287,128 | $(6,409,341) | $2,467,950,655 | $4,149,000 | $2,472,099,655 |
| Issuance of common stock from stock plan transactions | 1,115,693 | 66,942 | 6,283,742 | — | — | 6,350,684 | — | 6,350,684 |
| Repurchases of common stock | (8,802,415) | (528,145) | (35,111,663) | (166,527,240) | — | (202,167,048) | — | (202,167,048) |
| Stock-based compensation expense related to stock options, employee stock purchases and restricted stock | — | — | 16,160,289 | — | — | 16,160,289 | — | 16,160,289 |
| Dividends declared ($0.24 per share) | — | — | — | (53,321,754) | — | (53,321,754) | — | (53,321,754) |
| Capital contributions, net | — | — | — | — | — | — | 442,500 | 442,500 |
| Fair value of non-controlling interest in EyeLock LLC | — | — | — | — | — | — | 656,000 | 656,000 |
| Purchase of additional interest in BioCenturion LLC | — | — | 1,139,021 | — | — | 1,139,021 | (4,591,549) | (3,452,528) |
| Net income (1) | — | — | — | 190,913,629 | — | 190,913,629 | (56,395) | 190,857,234 |
| Other comprehensive income | — | — | — | — | 3,012,692 | 3,012,692 | — | 3,012,692 |
| BALANCE AS OF JUNE 30, 2025 | 219,520,750 | $13,171,245 | $998,911,809 | $1,421,351,763 | $(3,396,649) | $2,430,038,168 | $599,556 | $2,430,637,724 |
(1)Net income (loss) excludes net loss attributable to redeemable non-controlling interest of $539,730 and $332,739 for the six months ended June 30, 2026 and 2025, respectively (see Note 16).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.